Skip to main content

ADVERTISEMENT

Edward Goldberg, MD

Background: Vesicular monoamine transporter 2 (VMAT2) inhibitors including valbenazine are first-line therapies for tardive dyskinesia (TD), a persistent movement disorder associated with...
10/18/2020
10/08/2020